OraSure Technologies (OSUR) to Release Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is expected to release its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect OraSure Technologies to post earnings of ($0.17) per share and revenue of $26.4430 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR opened at $2.75 on Tuesday. OraSure Technologies has a fifty-two week low of $2.08 and a fifty-two week high of $4.22. The business has a 50 day moving average price of $2.64 and a two-hundred day moving average price of $2.78. The firm has a market cap of $197.26 million, a PE ratio of -3.44 and a beta of 0.87.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its position in shares of OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after buying an additional 878,151 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of OraSure Technologies by 6.4% during the second quarter. Geode Capital Management LLC now owns 1,869,868 shares of the medical instruments supplier’s stock valued at $5,611,000 after acquiring an additional 112,851 shares during the period. Cannell Capital LLC raised its holdings in OraSure Technologies by 33.7% during the second quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after purchasing an additional 470,536 shares in the last quarter. Kotler Kevin bought a new stake in OraSure Technologies during the fourth quarter worth approximately $4,359,000. Finally, Bridgeway Capital Management LLC lifted its position in OraSure Technologies by 9.5% in the second quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock worth $5,371,000 after purchasing an additional 154,985 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on OSUR shares. Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research report on Thursday, January 22nd. Stephens reduced their price objective on shares of OraSure Technologies from $3.50 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 12th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OraSure Technologies has an average rating of “Reduce” and an average target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.